Sugardown® — a diabetes drug candidate Revenue

About Sugardown® — a diabetes drug candidate

Sugardown® is a non-systemic, non-toxic, chewable dietary supplement developed to reduce the postprandial (post-meal) rise in blood glucose. The formulation is designed to act locally in the gastrointestinal tract without entering systemic circulation. Sugardown® works through two synergistic, localized mechanisms: - Enzymatic Binding: It binds to complex starch polysaccharides in food as well as to digestive enzymes such as amylase, thereby reducing enzymatic breakdown of carbohydrates into glucose. - Intestinal Barrier Modulation: It forms a temporary coating along the lumen of the small intestine, slowing glucose absorption into the bloodstream. Together, these actions result in a slower rate of glucose uptake, effectively reducing postprandial glycemic and insulin responses. Clinical trial demonstrated a statistically significant reduction in postprandial blood glucose and insulin levels. In addition to glycemic regulation, Sugardown® exhibits prebiotic properties. By altering carbohydrate availability in the gut, it helps promote the growth of beneficial microbiota, contributing to improved metabolic balance and gut health over time. Key Characteristics : Form: Chewable tablet Action: Local (non-systemic), mechanical-chemical Safety: Non-toxic, plant-based Indications: Prediabetes, metabolic syndrome, glucose management Differentiation: Dual-action mechanism + microbiome support

View contact profiles from Sugardown® — a diabetes drug candidate